These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28826192)

  • 1. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
    McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
    McGarry A; Auinger P; Kieburtz K; Geva M; Mehra M; Abler V; Grachev ID; Gordon MF; Savola JM; Gandhi S; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2020; 9(2):173-184. PubMed ID: 32508327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Reilmann R; Anderson KE; Feigin A; Tabrizi SJ; Leavitt BR; Stout JC; Piccini P; Schubert R; Loupe P; Wickenberg A; Borowsky B; Rynkowski G; Volkinshtein R; Li T; Savola JM; Hayden M; Gordon MF;
    Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.
    McGarry A; Leinonen M; Kieburtz K; Geva M; Olanow CW; Hayden M
    J Huntingtons Dis; 2020; 9(4):371-380. PubMed ID: 33164941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
    Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
    J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chen S; Liang T; Xue T; Xue S; Xue Q
    Front Neurol; 2021; 12():658123. PubMed ID: 34054700
    [No Abstract]   [Full Text] [Related]  

  • 11. One-year safety and tolerability profile of pridopidine in patients with Huntington disease.
    Squitieri F; Landwehrmeyer B; Reilmann R; Rosser A; de Yebenes JG; Prang A; Ivkovic J; Bright J; Rembratt A
    Neurology; 2013 Mar; 80(12):1086-94. PubMed ID: 23446684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
    Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.
    Rabinovich-Guilatt L; Siegler KE; Schultz A; Halabi A; Rembratt A; Spiegelstein O
    Br J Clin Pharmacol; 2016 Feb; 81(2):246-55. PubMed ID: 26407011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
    Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
    Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.
    Esmaeilzadeh M; Kullingsjö J; Ullman H; Varrone A; Tedroff J
    Clin Neuropharmacol; 2011; 34(3):95-100. PubMed ID: 21586914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.
    Asla MM; Nawar AA; Abdelsalam A; Elsayed E; Rizk MA; Hussein MA; Kamel WA
    Mov Disord Clin Pract; 2022 Jan; 9(1):20-30. PubMed ID: 35005061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pridopidine paradox in Huntington's disease.
    Reilmann R
    Mov Disord; 2013 Sep; 28(10):1321-4. PubMed ID: 23847099
    [No Abstract]   [Full Text] [Related]  

  • 19. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
    Squitieri F; de Yebenes JG
    Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.